|
Toggle Summary
September 2, 2020
|
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
WALTHAM, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15 th
|
Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference
|
|
Toggle Summary
August 13, 2020
|
Minerva Neurosciences to Present at JMP Securities CNS Forum
WALTHAM, Mass. , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities
|
Minerva Neurosciences to Present at JMP Securities CNS Forum
|
|
Toggle Summary
August 3, 2020
|
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
WALTHAM, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the
|
Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates
|
|
Toggle Summary
July 27, 2020
|
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
Management to host conference call WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020
|
|
Toggle Summary
July 1, 2020
|
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass.
|
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
|
|
Toggle Summary
June 1, 2020
|
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
WALTHAM, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the company will hold a webcast on Friday, June 5, 2020
|
REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
May 29, 2020
|
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score (p ≤0.064 and 0.259, respectively), or the key secondary endpoint, the Personal and Social Performance Scale Total Score (p
|
Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
|
|
Toggle Summary
May 4, 2020
|
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
Top line results from pivotal Phase 3 trial with roluperidone in negative symptoms in patients diagnosed with schizophrenia on track for release in second quarter WALTHAM, Mass. , May 04, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company
|
Minerva Neurosciences Reports First Quarter 2020 Financial Results and Business Updates
|
|
Toggle Summary
April 27, 2020
|
Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
Management to host conference call WALTHAM, Mass. , April 27, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release
|
Minerva Neurosciences to Report First Quarter 2020 Financial Results and Business Updates on May 4, 2020
|
|
Toggle Summary
March 24, 2020
|
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
Call at 8:00 a.m. Eastern Time on Tuesday, March 31, 2020 WALTHAM, Mass. , March 24, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies addressing high unmet medical needs in the treatment of
|
MINERVA NEUROSCIENCES TO HOST KEY OPINION LEADER MEETING ON ROLUPERIDONE: A POTENTIALLY NOVEL MECHANISM TO TREAT THE NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
|
